Skip to main content
Login
Contact
Subscribe
Search form
Search
Mammoth Times
Click for weather forecast
Home
Forms
News
Obituaries
Sports/Outdoors
Classifieds
Place an Ad
Photos
Videos
Games
Mountain
Snow Report
Ski Report
Road Conditions
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Aimmune Therapeutics, Inc.
< Previous
1
2
3
4
5
Next >
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years
February 25, 2021
Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis...
Tickers
AIMT
From
Business Wire News Releases
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers
August 24, 2020
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 07, 2020
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
July 30, 2020
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
July 23, 2020
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
Tickers
AIMT
From
Business Wire News Releases
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
July 21, 2020
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
Tickers
AIMT
From
Business Wire News Releases
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
July 06, 2020
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
Tickers
AIMT
From
Business Wire News Releases
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
June 08, 2020
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
Tickers
AIMT
From
Business Wire News Releases
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine Months
June 08, 2020
New Data Show Patients Are Highly Satisfied with and Confident in the Efficacy of Daily Treatment with PALFORZIA™ After Nine Months
Tickers
AIMT
From
Business Wire News Releases
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
June 01, 2020
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented
Tickers
AIMT
From
Business Wire News Releases
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
May 28, 2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1...
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
May 12, 2020
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
May 11, 2020
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
April 30, 2020
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
April 08, 2020
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
Tickers
AIMT
From
Business Wire News Releases
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
March 16, 2020
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Tickers
AIMT
From
Business Wire News Releases
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
March 13, 2020
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
February 27, 2020
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Present at Upcoming Investor Conferences
February 26, 2020
Aimmune Therapeutics to Present at Upcoming Investor Conferences
Tickers
AIMT
From
Business Wire News Releases
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
February 25, 2020
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
February 20, 2020
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
February 05, 2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health...
Tickers
AIMT
From
Business Wire News Releases
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
February 05, 2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide...
Tickers
AIMT
From
Business Wire News Releases
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
January 31, 2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and...
Tickers
AIMT
From
Business Wire News Releases
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Tickers
AIMT
From
Business Wire News Releases
Aimmune to Participate in Three Upcoming Investor Conferences
November 15, 2019
Aimmune to Participate in Three Upcoming Investor Conferences
Tickers
AIMT
From
Business Wire News Releases
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge
November 08, 2019
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study
Tickers
AIMT
From
Business Wire News Releases
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments
November 08, 2019
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments
Tickers
AIMT
From
Business Wire News Releases
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
November 08, 2019
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
Tickers
AIMT
From
Business Wire News Releases
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
November 08, 2019
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
Tickers
AIMT
From
Business Wire News Releases
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password